Welcome to Umecrine Mood
Umecrine Mood AB is developing novel products to treat the mental and physical symptoms associated with Premenstrual Dysphoric Disorder (PMDD) and serve Premenstrual Syndrome (PMS) caused by endogenous CNS-active steroids derived from the corpus luteum of the ovary. The company offers a unique and novel treatment principle based on modulation of GABA-steroid action.

The company portfolio includes newly discovered lead compounds and the selected drug candidate is a first-in-class compound, a GABAA modulating steroid antagonist (GAMSA), currently in clinical phase I.

The company is part of the Karolinska Development AB (publ).
















© 2010 Umecrine Mood   |   556698-0750   |   Registred office in Umeå BACK TO START